These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23686435)

  • 21. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study.
    Bai AD; Findlater A; Irfan N; Singhal N; Loeb M
    Int J Antimicrob Agents; 2021 Nov; 58(5):106429. PubMed ID: 34469802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis.
    Yetmar ZA; Razi S; Nayfeh T; Gerberi DJ; Mahmood M; Abu Saleh OM
    Int J Antimicrob Agents; 2022 Jan; 59(1):106486. PubMed ID: 34839007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twice daily cefazolin is effective for treatment of serious methicillin-sensitive
    Birrell MT; Fuller A
    Ther Adv Infect Dis; 2019; 6():2049936119882847. PubMed ID: 31839941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
    Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB
    Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive
    Hamad Y; Nickel KB; Olsen MA; George IA
    Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia.
    Davis JS; Turnidge J; Tong S
    Int J Antimicrob Agents; 2018 Aug; 52(2):297-300. PubMed ID: 29499317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.
    Li J; Echevarria KL; Hughes DW; Cadena JA; Bowling JE; Lewis JS
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5117-24. PubMed ID: 24936596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
    Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins.
    Bidell MR; Patel N; O'Donnell JN
    J Antimicrob Chemother; 2018 Oct; 73(10):2643-2651. PubMed ID: 30085140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis.
    Shi C; Xiao Y; Zhang Q; Li Q; Wang F; Wu J; Lin N
    BMC Infect Dis; 2018 Oct; 18(1):508. PubMed ID: 30305037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
    Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
    Trials; 2018 May; 19(1):297. PubMed ID: 29843781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea.
    Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB;
    Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT.
    Herrera-Hidalgo L; Luque-Márquez R; de Alarcon A; Guisado-Gil AB; Gutierrez-Gutierrez B; Navarro-Amuedo MD; Praena-Segovia J; Carmona-Caballero JM; Fraile-Ramos E; Gutierrez-Valencia A; Lopez-Cortes LE; Gil-Navarro MV
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation.
    Antosz K; Battle S; Chang J; Scheetz MH; Al-Hasan M; Bookstaver PB
    Pharmacotherapy; 2023 Jan; 43(1):85-95. PubMed ID: 36521869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of penicillins (penicillin G and ampicillin) and cefazolin as a definitive therapy against penicillin-susceptible Staphylococcus aureus (PSSA) bacteremia in Japan: a retrospective cohort study.
    Moriyama Y; Ishikane M; Mezaki K; Ohmagari N
    J Infect Chemother; 2020 Apr; 26(4):358-362. PubMed ID: 31822451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia.
    Rindone JP; Mellen CK
    Br J Clin Pharmacol; 2018 Jun; 84(6):1258-1266. PubMed ID: 29600576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy.
    Tice AD; Hoaglund PA; Shoultz DA
    Am J Med; 2003 Jun; 114(9):723-8. PubMed ID: 12829198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK
    Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
    Pollett S; Baxi SM; Rutherford GW; Doernberg SB; Bacchetti P; Chambers HF
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.